By Karen E. Roman Alladapt Immunotherapeutics, Inc., a clinical-stage company which develops therapeutics to address food allergies, announced data from its Phase 1/2 Harmony study which proves that ADP101, a multi-allergen oral immunotherapy (OIT), produced dose-dependent, clinically meaningful responses. The data was presented at the 2023 Annual Scientific Meeting of the American College of Asthma, […]
Alladapt Immunotherapeutics Presents Phase 1/2 Harmony Data Demonstrating Therapeutic Potential and Safety of ADP101 for the Treatment of Food Allergy at 2023 ACAAI Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.